News

Understanding, Preventing and Treating Long-Term Effects of COVID: RECOVER Study Enrolling Patients from Pacific Northwest

As part of a massive nationwide effort, ISB is leading a multi-site consortium for the NIH RECOVER (Researching COVID to Enhance Recovery) Initiative. The Pacific Northwest consortium is made up of ISB, Providence, Swedish, and University of Washington School of Medicine.

Predicting ‘Long COVID’ At Initial Point of COVID-19 Diagnosis

Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.

Drs. Jim Heath, Yapeng Su and Jihoon Lee

Metabolic Changes in Plasma and Immune Cells Associated with COVID-19 Severity, May Predict Patient Survival

Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. These findings are associated with COVID-19 severity and may predict patient survival. The work was published in the journal Nature Biotechnology.

Goldwater Scholar Daniel Chen

ISB Undergraduate Researcher Daniel Chen Earns Goldwater Scholarship

Daniel Chen, an undergraduate researcher in ISB’s Heath Lab and junior at the University of Washington, has been awarded a prestigious Goldwater Scholarship. Chen has been a key member of ISB’s COVID-19 Immune Response Study.

Jennifer Hadlock, Andrew Magis and Chengzhen Dai

COVID-19 Outcome Disparities Across Racial/Ethnic Lines

ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.

How Will Healthcare and Scientific Research Be Different in a Post-Pandemic World?

Providence President and CEO Dr. Rod Hochman joined ISB President and Professor Dr. Jim Heath for an hour-long conversation hosted by ISB and Town Hall Seattle about how healthcare and science will be different in a post-pandemic world.

COVID-19 Immune Response Study Could Lead to More Effective Treatments

Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar. 

View of the responsive recruitment website and electronic consent platform as seen on mobile phone and desktop devices.

ISB Builds Digital Platform for COVID-19 Research Study – and Beyond

In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.

Merck, ISB, Swedish Collaborate In Trial to Understand, Treat COVID-19

ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.